27 results
8-K
MLYS
Mineralys Therapeutics Inc
10 Jun 24
Other Events
4:02pm
Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act
S-3
EX-1.2
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Shelf registration
7:30am
routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect.
(xvii)Accuracy of Exhibits … litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or of any claim whatsoever based upon any such untrue
8-K
m6ey6rk8 tk38saiay9
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99.1
hayq5lvrdkvcy502 tw
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-10.1
0x7i00t
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99
am3fcq6zo 0q4dkg
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
EX-99.1
q3t0z05i3kcyx
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
EX-99.1
8gijsk1a 7c
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
v4hrjjg6
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
EX-99.1
en8va2erwo79yeppaa4d
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
xcqvucm7stf858uq6rv
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
EX-99.1
22zkh81k dhs6u3zri5e
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
rfi01uzgu
17 Jul 23
Regulation FD Disclosure
4:03pm
10-Q
br1wozxld
15 May 23
Quarterly report
5:25pm